JERUSALEM, June 4 Oramed Pharmaceuticals, Inc.(OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral deliverysystems, announced today that it has been selected to display its abstract,entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin inHealthy Subjects, at the upcoming 68th Annual American Diabetes Association'sScientific Sessions Conference in San Francisco, highlighting the successfulresults from its oral insulin trials on healthy volunteers.
The abstract will also be printed in the Scientific Sessions AbstractBook, the June 2008 supplement to the journal Diabetes.
Oramed's technology will be included in an oral presentation by Prof. Dr.Lutz Heinemann, CEO of Profil Institute for Metabolic Research,"Pharmacokinetics and Pharmacodynamics of Alternate Insulin DeliverySystems," on Saturday, June 7, 2008 from 4 pm to 6 pm.
"The selection of Oramed as one of the companies to exhibit at ScientificSessions is a great opportunity that allows us to present our data from humantrials to the leading scientists in the diabetes field from all over theworld," said Nadav Kidron, Oramed CEO.
Oramed's abstract poster has been assigned presentation number 425-PClinical Therapeutics/New Technology - Insulin Delivery Systems and isavailable for viewing throughout the conference. A representative of thecompany will be available to answer questions on Saturday, June 7 from 6-7PMand from 12-2PM on Monday, June 9 at San Francisco's Moscone ConventionCenter, Hall D.
For more information about the ADA and the upcoming conference, pleasevisit http://professional.diabetes.org.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inphase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research by top research scientists at Jerusalem's HadassahMedical Center. The Company's corporate and R&D headquarters are based inJerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relation Contacts: Oramed Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, Email: [email protected]
. Media Contacts: Ruder Finn Israel for Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office: +972-2-589-2003, Email: [email protected]
SOURCE Oramed Pharmaceuticals Inc.